investigators – Page 3 – Communicable Diseases Research

Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19 A Phase 2 Randomized Clinical Trial

경증에서 중등도의 COVID-19 A 2상 무작위 임상 시험에서 SARS-CoV-2 호흡기 바이러스 제거, 바이러스 배출 및 증상 지속 기간에서 니클로사미드 대 위약의 효능

Randomized Controlled Trial

Published on 2022-02-092022-09-10
Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 신약개발, 임상, 치료제,

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

입원한 COVID-19 환자를 위한 과면역 면역글로불린(ITAC): 이중 맹검, 위약 대조, 3상, 무작위 시험

Clinical Trial

Published on 2022-02-052022-09-11
Journal: Lancet (London, England) [Category] Fulltext, MERS, 임상, 진단, 치료제,

[키워드] 1:1 95% CI addition adjusted Administered adverse events Analysis Anti-spike antibody assigned baseline carried clinical care clinical trials Complication COVID-19 death donors double-blind duration of symptoms Efficacy Efficacy and safety eligibility criteria end-organ Endpoint enrolled Evidence evidence of Factors finding greater Group allocation heterogeneity hospitalised hospitalised patient Hospitalised patients hyperimmune Immunoglobulin Immunotherapy Infection infusion Interaction International Intravenous immunoglobulin investigators mass mITT mITT analysis modified intention-to-treat Neutralising Antibodies neutralising antibody Organ failure outbreak outcome participant Passive Patient Phase 3 Placebo placebo group placebo-controlled placebo-controlled trial positive Primary outcome randomisation randomised randomised clinical trial Randomised trial Randomly ranged reaction receive Registered Remdesivir Research risk Saline SARS-CoV-2 serious infections significantly Standard of care stratified subgroup subgroups Symptom symptomatic therapy to define Treatment treatment of COVID-19 Trial trial participant trial participants Volume was measured were used with COVID-19
[DOI] 10.1016/S0140-6736(22)00101-5 PMC 바로가기 [Article Type] Clinical Trial

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

COVID-19(DisCoVeRy)로 입원한 환자의 치료를 위한 렘데시비르 + 표준 치료 대 표준 치료 단독: 3상, 무작위, 대조, 공개 시험

Clinical Trial

Published on 2022-02-012022-09-11
Journal: The Lancet. Infectious Diseases [Category] Fulltext, MERS, 임상, 치료법, 치료제,

[키워드] Abstract activities activity acute respiratory distress acute respiratory distress syndrome adaptive Administered Adult patient Adult patients Analysis antiviral efficacy assigned Bacterial infection Belgium block Breastfeeding Chronic kidney disease clinical clinical benefit Clinical efficacy clinical evidence Clinical research clinical status Combination Commission computer-generated conducted control group Controlled trial COVID-19 criteria death development discharged distribution elevated elevated liver enzymes eligible enrolled Europe European evaluate evidence of exclusion criteria extracorporeal membrane oxygenation followed by France French group Health care hepatorenal syndrome high flow oxygen devices hospital hospitalised Hydroxychloroquine Inclusion indication Innovation intention-to-treat population interferon interferon beta Interferon beta-1a intravenous intravenous infusion Invasive mechanical ventilation investigators Kidney disease laboratory-confirmed SARS-CoV-2 infection limitation liver enzymes Lopinavir Lopinavir-ritonavir Luxembourg material Ministry of Health modified intention-to-treat multicentre no significant difference non-invasive ventilation not significant Occurrence Odds ratio once daily one health Open-label Ordinal Scale oxygen oxygen supplementation oxygen support participant Patient Phase 3 Pneumonia Portugal Pregnancy Primary outcome random assignment randomisation randomised Randomly receive Regional Registered Remdesivir required requiring supplemental oxygen respiratory distress ribavirin Ritonavir Safety SARS-CoV-2 SARS-COV-2 infection Secondary outcomes Serious Adverse Event Serious Adverse Events seven-point ordinal scale Severity of disease Sponsor Standard of care stratified supplemental oxygen Support symptomatic syndrome the WHO translation Treatment treatment group treatment groups Trial Tumor union ventilator were excluded WHO ordinal scale with COVID-19
[DOI] 10.1016/S1473-3099(21)00485-0 PMC 바로가기 [Article Type] Clinical Trial

HIV and Aging in the Era of ART and COVID-19

예술과 코로나19 시대의 HIV와 노화

Article

Published on 2022-02-012022-09-11
Journal: Journal of acquired immune deficiency syndromes (1 [Category] COVID19(2023년), SARS, 치료제,

[키워드] aging AIDS Antiretroviral therapy ART article center clinician contributed COVID-19 HIV HIV/AIDS investigators Miami organized Patient progression provide the disease
[DOI] 10.1097/QAI.0000000000002835 PMC 바로가기 [Article Type] Article

Navigating ethical challenges of conducting randomized clinical trials on COVID-19

COVID-19에 대한 무작위 임상 시험 수행의 윤리적 문제 탐색

Commentary

Published on 2022-01-282022-09-10
Journal: Philosophy, Ethics, and Humanities in Medicine : P [Category] SARS, 임상,

Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study

COVID-19에 의한 혼란에 대한 반응으로 알츠하이머 병 임상 시험에 대한 잠재적 수정의 영향 : 시뮬레이션 연구

Research

Published on 2021-12-202022-09-10
Journal: Alzheimer's Research & Therapy [Category] SARS, 치료기술,

[키워드] accounted adaptive affected Alzheimer Alzheimer disease Alzheimer’s disease Analysis assessments biases change changes changes in Changing clinical trial clinical trials completion COVID-19 COVID-19 pandemic datasets detect disease Disease modification Effect effect size Enrollment examined expected idea Impact investigator investigators linear maintain Mild cognitive impairment Modification outcome outcomes pandemic performed randomized clinical trial RCT RCTs Result risk Simulation Simulations Sponsor Statistical power Support symptomatic Symptomatic treatment threat Threats Treatment treatment period Trial trials Validity was determined
[DOI] 10.1186/s13195-021-00938-w PMC 바로가기 [Article Type] Research

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

Clinical Trial

Published on 2021-12-112022-10-05
Journal: Lancet (London, England) [Category] Fulltext, MERS, 임상,

[키워드] 1:1 95% CI absence Administered Adults adverse event age Analysis anaphylaxis assigned Bharat chronic conditions clinical Clinical efficacy clinical trial clinically clinics computer-generated Council COVID-19 COVID-19 infection Cutoff deaths dependent on distribution dose double-blind Efficacy evaluate Follow-up groups healthy hospital immunocompromising condition immunological immunosuppressive inactivated India interim analysis intramuscular dose investigators laboratory-confirmed median medical condition multicentre Nurse occurred Occurrence outcome outcomes participant Participants per-protocol population Phase 3 phase 3 trial Placebo placebo group placebo recipients placebo-controlled Primary outcome proportion raised randomisation randomised Randomly reactogenicity receive recipient recruited Registered registry reported Research safety population SARS-CoV-2 vaccine second dose Serious Adverse Event seronegative participant severity significant difference Sponsor stratified study population symptomatic symptomatic COVID-19 disease the vaccine therapy Toll-like receptor Treatment treatment group Trial Vaccine virion
[DOI] 10.1016/S0140-6736(21)02000-6 PMC 바로가기 [Article Type] Clinical Trial

Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence

SARS-CoV-2 감염의 조기 치료를 위한 Fluvoxamine: 현재 증거 검토

Review

Published on 2021-12-012022-09-11
Journal: Drugs [Category] SARS, 비임상, 임상,

[키워드] anti-inflammatory effect Anti-inflammatory effects appear available data breath Canada cause Clinical deterioration clinician condition controlled trials COVID-19 COVID-19 pandemic COVID-19 treatment COVID-19 treatment guidelines current cytokine production Decision making Dosing early treatment Efficacy fluvoxamine Infection inhibitor investigators knowledge long-lasting mechanism medication meeting morbidity morbidity and mortality NIH observational study potential mechanism potential mechanisms Psychiatric randomized clinical trial Randomized controlled trial receptor reduce Research review Safe SARS-CoV-2 SARS-COV-2 infection selective Sepsis Serotonin Treatment Trial USA
[DOI] 10.1007/s40265-021-01636-5 PMC 바로가기 [Article Type] Review

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

건강한 소아 및 청소년을 대상으로 한 불활성화 SARS-CoV-2 백신(CoronaVac)의 안전성, 내약성 및 면역원성: 이중 맹검, 무작위, 대조, 1/2상 임상 시험

Clinical Trial

Published on 2021-12-012022-09-12
Journal: The Lancet. Infectious Diseases [Category] MERS, SARS, 임상, 진단, 치료기술,

[키워드] 95% CI Adverse reaction age All participants aluminum Antibody Response Antibody titre assigned Beijing block Block randomisation center children China Chinese clinical trial Control CoronaVac COVID-19 pandemic COVID-19 vaccine detectable development dose dose-escalation double-blind Endpoint enrolled geometric mean titre groups healthy children Humoral response hydroxide inactivated individual Infection injection injection site Intramuscular injection investigators Laboratory live SARS-CoV-2 Mild moderate MOST neutralising antibody occurred Pain participant Participants per-protocol population phase 1 trial Pneumonia prevention primary immunogenicity Program randomised Randomly receive Registered reported Safe Safety safety population safety profile SARS-CoV-2 SARS-CoV-2 vaccine Science second dose Serious Adverse Event Seroconversion seroconversion rate severity significant difference Support technology three group Tolerability vaccination Vaccine were excluded
[DOI] 10.1016/S1473-3099(21)00319-4 PMC 바로가기 [Article Type] Clinical Trial

Developing a virtual assessment protocol for the AMPLIFI Randomized Controlled Trial due to COVID-19: From assessing participants’ preference to preparing the team

COVID-19로 인한 AMPLIFI Randomized Controlled Trial을 위한 가상 평가 프로토콜 개발: 참가자의 선호도 평가에서 팀 준비까지

Article

Published on 2021-12-012022-09-11
Journal: Contemporary clinical trials [Category] SARS, 임상,